

Market insights summary

United States peripheral bioresorbable stent market

What's new and trending?

A major advancement in small-vessel treatment option

- **First FDA-approved:** Abbott Laboratories' Esprit below-the-knee (BTK) system became the first FDA-approved drug-coated bioresorbable stent (BRS) for chronic limb-threatening ischemia (CLTI)
- **Superior clinical outcomes:** BRS treatment offers superior long-term outcomes compared to traditional treatment
- **Revived interest in BRS platforms:** This has sparked renewed interest in BRS technology for interventional cardiology and other small vessel treatments

"BRS will likely take over the market [for treatment of] small vessels with such small flow."

–Vascular Surgeon, US

"You will need some years [to see the clinical results]. [With long-term results, BRS adoption] will increase exponentially and reach 70-80% in 10 years."

–Vascular Surgeon, US

Access more insights and data in the [report](#).
[Speak to our team](#) to see how we can power your innovation.

2024 U.S. peripheral bioresorbable stent market snapshot


\$2.23M

Market value


19.9%

CAGR ('24 - '33)


U.S. CLTI prevalent cases



U.S. BTK stent market, by product type



Peripheral BRS vs. coronary DES pricing



*BTK stenting performed with off-label use of coronary DES

More BTK BRS brands are currently in development and looking to enter the market:

- R3 Vascular's Magnitude
- BIOTRONIK's Freesolve BTK
- Efemoral Medical's Efemoral BRS